NextCure, Inc. rose 17.6% on Monday, November 9, 2026, on 58,474 shares. No headline about NXTC came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
NextCure, Inc. (NXTC:NASDAQ) closed at $5.98 on November 10, 2026, down 4.63% on the day. The stock trades 62.0% below its 52-week high of $15.74 and 285.8% above its 52-week low of $1.55. Over the past year, it lost 29.8%. NextCure, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, NXTC closed higher on 117 days (46%). Its best day was July 14, 2026 (+201.83%) and its worst was June 1, 2026 (-45.48%). The stock moved 10% or more in a single session 34 times. It opened at least 5% above the previous day's high 3 times.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.
Find more stocks like NXTC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.